Acte­lion’s R&D group slammed with a set­back as ex­ecs fi­nal­ize $30B J&J deal

Acte­lion’s R&D group will spin off in­to a new biotech soon with a sting­ing set­back to deal with.

The Swiss biotech, which has been at work fi­nal­iz­ing the $30 bil­lion J&J deal to ac­quire the com­mer­cial drug port­fo­lio and part­ner on the ex­per­i­men­tal pipeline, an­nounced ear­ly Thurs­day that it racked up one win and one loss in Phase III for its an­tibi­ot­ic cada­zol­id.

That’s all we know and ev­i­dent­ly about all we’re go­ing to find out right now. In a short state­ment the biotech said that their an­tibi­ot­ic had been test­ed in a Phase III pro­gram with 1,263 pa­tients, com­par­ing 250 mg of cada­zol­id twice dai­ly against 4 dai­ly dos­es of 125 mg van­comycin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.